IMC-1C11 Biosimilar – Anti-VEGFA mAb – Research Grade from ProteoGenix; catalogue PX-TA1132; research use only.
Know who made it. See the evidence. Buy through one marketplace.
IMC-1C11 Biosimilar is a novel antibody drug that targets vascular endothelial growth factor A (VEGFA) and is used for the treatment of various diseases. In this article, we will delve into the structure, activity, and applications of IMC-1C11 Biosimilar in detail.
IMC-1C11 Biosimilar is a monoclonal antibody (mAb) that is produced using recombinant DNA technology. It is a biosimilar version of the anti-VEGFA mAb, bevacizumab. The antibody has a molecular weight of approximately 149 kDa and is composed of two identical heavy chains and two identical light chains. The heavy chains are approximately 50 kDa in size and the light chains are approximately 25 kDa. IMC-1C11 Biosimilar also contains two disulfide bonds that help in maintaining its structure and stability.
IMC-1C11 Biosimilar works by binding to VEGFA, a protein that plays a crucial role in the formation of new blood vessels. It is a potent inhibitor of VEGFA and prevents the binding of VEGFA to its receptor, VEGFR-2. This leads to the inhibition of VEGFA signaling, which is essential for the growth and survival of tumors. By blocking VEGFA, IMC-1C11 Biosimilar inhibits angiogenesis (formation of new blood vessels) and reduces tumor growth and metastasis.
IMC-1C11 Biosimilar has shown promising results in various preclinical and clinical studies. It has been approved for the treatment of several types of cancers, including colorectal, lung, breast, and ovarian cancer. It is also being investigated for its potential use in other diseases, such as age-related macular degeneration, diabetic retinopathy, and rheumatoid arthritis.
IMC-1C11 Biosimilar has been approved for the treatment of metastatic colorectal cancer. In a phase III clinical trial, it was shown to significantly improve progression-free survival and overall survival when used in combination with chemotherapy. It is also being investigated for its use in earlier stages of colorectal cancer.
cancer is the leading cause of cancer-related deaths worldwide. IMC-1C11 Biosimilar has shown promising results in the treatment of non-small cell lung cancer (NSCLC). In a phase III clinical trial, it was shown to significantly improve overall survival when used in combination with chemotherapy. It is also being investigated for its use in other types of lung cancer.
IMC-1C11 Biosimilar is also approved for the treatment of metastatic breast cancer. In a phase III clinical trial, it was shown to significantly improve progression-free survival when used in combination with chemotherapy. It is also being investigated for its use in other types of breast cancer, including HER2-positive breast cancer.
cancer is the fifth leading cause of cancer-related deaths among women. IMC-1C11 Biosimilar has shown promising results in the treatment of ovarian cancer. In a phase III clinical trial, it was shown to significantly improve progression-free survival when used in combination with chemotherapy. It is also being investigated for its use in other types of ovarian cancer.
IMC-1C11 Biosimilar is a novel antibody drug that specifically targets VEGFA and has shown promising results in the treatment of various types of cancers. Its unique mechanism of action makes it a valuable therapeutic option for patients with cancer. With ongoing research and clinical trials, IMC-1C11 Bios
ProteoGenix catalogue number PX-TA1132. For research use only.
Target: IMC-1C11 Biosimilar – Anti-VEGFA mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| IMC-1C11 Biosimilar – Anti-VEGFA mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
